Cost&ndash;utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Cost&ndash;utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo1,2, Sergio Di Matteo2, Maria Elisa Mancuso3, Elena Santagostino31University of Pavia, School of Pharmacy, Pavia, Italy; 2S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 3Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca&#39; Granda, Os...

Full description

Bibliographic Details
Main Authors:	Maria Elisa Mancuso, Sergio Di Matteo, Giorgio L Colombo, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-03-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/costndashutility-analysis-of-prophylaxis-versus-treatment-on-demand-in-a6675

Similar Items

A cost&ndash;utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
by: Giorgio L Colombo, et al.
Published: (2009-10-01)

Prophylaxis versus on-demand regimens to prevent arthropathy in real-life patients with hemophilia A
by: Shi-JieLai, et al.
Published: (2018)

Optimization of prophylaxis for hemophilia A.
by: Robert D Herbert, et al.
Published: (2018-01-01)

Correction: Optimization of prophylaxis for hemophilia A.
by: Robert D Herbert, et al.
Published: (2018-01-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
by: Runhui Wu, et al.
Published: (2021-08-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

Cost-effectiveness of combination fluticasone propionate&ndash;salmeterol 250/50 &mu;g versus salmeterol in severe COPD patients
by: An, et al.
Published: (2010-06-01)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
by: Di Minno G, et al.
Published: (2019-01-01)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
by: Batt K, et al.
Published: (2019-06-01)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
by: Christian Qvigstad, et al.
Published: (2020-02-01)

Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: An administrative claims analysis
by: Chawla, A., et al.
Published: (2021)

Hemophilia A in Brazil – epidemiology and treatment developments
by: Ferreira AA, et al.
Published: (2014-09-01)

Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
by: Rasekh HR, et al.
Published: (2011-11-01)

Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States
by: Adamski, K., et al.
Published: (2022)

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A
by: Prakas Kumar Mandal, et al.
Published: (2019-01-01)

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A
by: Hans-Christoph Rossbach
Published: (2010-01-01)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein&ndash;Barr virus disease
by: Heather&nbsp;E Vezina, et al.
Published: (2009-12-01)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
by: Michael Wang, et al.
Published: (2020-08-01)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
by: Stacy E. Croteau, et al.
Published: (2020-02-01)

Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India
by: Nita Radhakrishnan, et al.
Published: (2021-06-01)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
by: Brigid Unim, et al.
Published: (2015-01-01)

The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study
by: Hoefnagels JW, et al.
Published: (2020-01-01)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
by: Antoine Lafuma, et al.
Published: (2011-03-01)

Combined posterior lumbar plexus&ndash;sciatic nerve block versus combined femoral&ndash;obturator&ndash;sciatic nerve block for ACL reconstruction
by: Ayman I Tharwat
Published: (2011-02-01)

Masculinity Challenges for Men With Severe Hemophilia
by: Kenneth Reinicke, et al.
Published: (2019-08-01)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
by: Alanna McEneny-King, et al.
Published: (2017-10-01)

Erratum:&nbsp;An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967&ndash;976
by: Colombo GL, et al.
Published: (2009-02-01)

Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement
by: Gue D, et al.
Published: (2015-12-01)

Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents
by: Shannon Jackson, et al.
Published: (2019-04-01)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
by: Pratima Chowdary, et al.
Published: (2019-07-01)

Renal transplant in a patient of severe hemophilia
by: Sandeep Malik, et al.
Published: (2021-01-01)

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics
by: Farrugia A, et al.
Published: (2015-06-01)

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis
by: V Nicosia, et al.
Published: (2008-09-01)

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
by: Saba HI, et al.
Published: (2012-05-01)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014-03-01)

GlycoPEGylated recombinant factor IX for hemophilia B in context
by: Santagostino E, et al.
Published: (2018-09-01)

Validity and reliability of the Structured Clinical Interview for Depersonalization&ndash;Derealization Spectrum (SCI-DER)
by: Marco Mula, et al.
Published: (2008-08-01)

Perceptions of Men With Moderate to Severe Hemophilia Regarding the Management of Their Chronic Disorder and Utilization of Community-Based Support
by: Erik B. Rolstad MSW, PhD
Published: (2015-11-01)

MRSA and cataract surgery &ndash; reflections for practice
by: LF Porter, et al.
Published: (2010-10-01)